The inverted pyramid of biomarker-driven trials

Nature Reviews Clinical Oncology

Volumn 8, Issue 9, 2011, Pages 562-566

  Garrido Laguna, Ignacio ^a   Hidalgo, Manuel ^b   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SORAFENIB; TRASTUZUMAB; VEMURAFENIB;

ADVANCED CANCER; BASAL CELL CARCINOMA; BREAST CANCER; CANCER STAGING; COLORECTAL CANCER; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GENE SEQUENCE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 80052228891     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.113     Document Type: Review

References (61)

1. DiMasi, J. A. & Grabowski, H. G. Economics of new oncology drug development. J. Clin. Oncol. 25, 209-216 (2007). (Pubitemid 350003036)
2. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
3. Walker, I. & Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15-16 (2009).
4. Horstmann, E. et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N. Engl. J. Med. 352, 895-904 (2005). (Pubitemid 40300298)
5. Kurzrock, R. & Benjamin, R. S. Risks and benefits of phase 1 oncology trials, revisited. N. Engl. J. Med. 352, 930-932 (2005). (Pubitemid 40300304)
6. Postel-Vinay, S. et al. Clinical benefit in phase-I trials of novel molecularly targeted agents: Does dose matter? Br. J. Cancer 100, 1373-1378 (2009).
7. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001). (Pubitemid 32267972)
8. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172 (2009).
9. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
10. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
11. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
12. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007). (Pubitemid 46972777)
13. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
14. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006). (Pubitemid 44917502)
15. Janku, F. et al. Outcomes of phase II clinical trials in advanced metastatic non-small-cell lung cancer published within the last decade [abstract]. Ann. Oncol. 21 (8 Suppl.), viii127 (2010).
16. Gupta, S. et al. Dose of the molecularly targeted agents in phase 1 trials correlates with clinical benefit. Presented at the 22nd EORTC-NCI-AACR Symp. on Molecular Targets and Cancer Therapeutics. 17. Janku, F. et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 10, 558-565 (2011).
17. Von Hoff, D. D. et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877-4883 (2010).
18. Doroshow, J. H. Selecting systemic cancer therapy one patient at a time: Is there a role for molecular profiling of individual patients with advanced solid tumors? J. Clin. Oncol. 28, 4869-4871 (2010).
19. Gray, R. et al. Phase II clinical trial design: Methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin. Cancer Res. 12, 1966-1969 (2006).
20. Stewart, D. J. & Kurzrock, R. Cancer: The road to Amiens. J. Clin. Oncol. 27, 328-333 (2009).
21. El-Maraghi, R. H. & Eisenhauer, E. A. Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J. Clin. Oncol. 26, 1346-1354 (2008).
22. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
23. Bonadonna, G. & Valagussa, P. Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 304, 10-15 (1981). (Pubitemid 11212891)
24. Budman, D. R. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst. 90, 1205-1211 (1998). (Pubitemid 28407086)
25. Feldman, D. R. et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: Results and prognostic factor analysis. J. Clin. Oncol. 28, 1706-1713 (2010).
26. Stadtmauer, E. A. et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med. 342, 1069-1076 (2000). (Pubitemid 30207689)
27. Bengala, C. et al. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: Retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 36, 25-31 (2005). (Pubitemid 40946047)
28. Jain, R. K. et al. Phase I oncology studies: Evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin. Cancer Res. 16, 1289-1297 (2010).
29. Tanaka, C. et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol. 26, 1596-1602 (2008).
30. Adjei, A. A. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J. Clin. Oncol. 24, 4054-4055 (2006). (Pubitemid 46622278)
31. Kantarjian, H. M. et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101, 473-475 (2003). (Pubitemid 36077567)
32. Quintela-Fandino, M. et al. Phase I combination of sorafenib and erlotinib therapy in solid tumors: Safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol. Cancer Ther. 9, 751-760 (2010).
33. Goulart, B. H. et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin. Cancer Res. 13, 6719-6726 (2007). (Pubitemid 350206809)
34. Postel-Vinay, S. et al. Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities? J. Clin. Oncol. 29, 1728-1735 (2011).
35. Garrido-Laguna, I. et al. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-Approved treatment. Clin. Cancer Res. 16, 4031-4037 (2010).
36. Hidalgo, M. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001). (Pubitemid 32591445)
37. Paez, J. G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). (Pubitemid 38720929)
38. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
39. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001). (Pubitemid 32267973)
40. Van Cutsem, E.et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011-2019 (2011).
41. Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
42. Iadevaia, S., Lu, Y., Morales, F. C., Mills, G. B. & Ram, P. T. Identification of optimal drug combinations targeting cellular networks: Integrating phosphoproteomics and computational network analysis. Cancer Res. 70, 6704-6714 (2010).
43. Van den Abbeele, A. D. The lessons of GIST-PET and PET/CT: A new paradigm for imaging. Oncologist 13, 8-13 (2008).
44. Ma, W. W. et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J. Clin. Oncol. 27, 2697-2704 (2009).
45. Olive, K. P. et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
46. D. D. Von Hoff, R. et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study [abstract]. J. Clin. Oncol. 27 (15 Suppl.), 4525 (2009).
47. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007). (Pubitemid 350134889)
48. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
49. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
50. Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
51. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
52. Thomas, R. K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007). (Pubitemid 46328493)
53. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715-721 (2010).
54. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
55. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793-798 (2010).
56. Dupont Jensen, J. et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin. Cancer Res. 17, 667-677 (2011).
57. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
58. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
59. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002). (Pubitemid 34879334)
60. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
61. Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3-8 (2010).